Tetrofosmin
As of the edition of 20 October 2026, Tetrofosmin is a small molecule: marketed, first approved in 1999 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2003
- Kind
- Small molecule
- Brand name
- Myoview
- First approved
- 3 June 1999 (CH)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- GE Healthcare; 2 holders in all
- Registered trials
- 2, 1 stopped early
- Disease areas
- Cancer; Digestive system; Heart and blood vessels; Hormones; Pregnancy and women's health; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GE Healthcare | Applicant | 1999 to now |